Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dara L Aisner

Showing results (31-40 of 130) with videos related to

Pageof 13
Sort By:
Academic Pathology|August 16, 2023
The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathologyDara L Aisner, Christopher D Gocke, Daniel Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2017
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung CancerEmily R York, Marileila Varella-Garcia, Tami J Bang, et al.
The American Journal of Surgical Pathology|November 16, 2011
Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterizationB K Kleinschmidt-DeMasters, Diane K Birks, Dara L Aisner, et al.
JCO Precision Oncology|March 31, 2022
<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast CancerAryana R Rasti, Amy Guimaraes-Young, Farrah Datko, et al.
Clinical Lung Cancer|November 6, 2023
CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS ProgressionJames M Jurica, Billie Carsten, Sudabeh Balakhani, et al.
The Journal of Molecular Diagnostics : JMD|February 10, 2016
A Suggested Molecular Pathology Curriculum for Residents: A Report of the Association for Molecular PathologyDara L Aisner, Anna Berry, D Brian Dawson, et al.
JCO Precision Oncology|December 5, 2024
Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an <i>EGFR::ERBB4</i> Fusion Through Use of EGFR Tyrosine Kinase InhibitorsAmy Guimaraes-Young, Kurtis D Davies, Patricia Trevisan, et al.
The Oncologist|August 27, 2015
Targeting the WNT Signaling Pathway in Cancer TherapeuticsDavid Tai, Keith Wells, John Arcaroli, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Copy Number-Low/TP53 Mutated Endometrial Cancer With Wild Type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next Generation Sequencing for Molecular ClassificationJoseph T Rabban, Rebecca J Wolsky, Neslihan Kayraklioglu, et al.
Frontiers in Medicine|February 8, 2021
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for <i>RET</i> FusionsRoy S Herbst, Dara L Aisner, Joshua R Sonett, et al.
Pageof 13

Showing results (31-40 of 130) with videos related to

Sort By:
Pageof 13
Academic Pathology|August 16, 2023
The Genomics Organization for Academic Laboratories (GOAL): A vision for a genomics future for academic pathologyDara L Aisner, Christopher D Gocke, Daniel Jones, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 10, 2017
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR-Mutant Non-Small Cell Lung CancerEmily R York, Marileila Varella-Garcia, Tami J Bang, et al.
The American Journal of Surgical Pathology|November 16, 2011
Atypical teratoid/rhabdoid tumor arising in a ganglioglioma: genetic characterizationB K Kleinschmidt-DeMasters, Diane K Birks, Dara L Aisner, et al.
JCO Precision Oncology|March 31, 2022
<i>PIK3CA</i> Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast CancerAryana R Rasti, Amy Guimaraes-Young, Farrah Datko, et al.
Clinical Lung Cancer|November 6, 2023
CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS ProgressionJames M Jurica, Billie Carsten, Sudabeh Balakhani, et al.
The Journal of Molecular Diagnostics : JMD|February 10, 2016
A Suggested Molecular Pathology Curriculum for Residents: A Report of the Association for Molecular PathologyDara L Aisner, Anna Berry, D Brian Dawson, et al.
JCO Precision Oncology|December 5, 2024
Clinical and Radiographic Benefit of a Patient With Metastatic Non-Small Cell Lung Cancer Harboring an <i>EGFR::ERBB4</i> Fusion Through Use of EGFR Tyrosine Kinase InhibitorsAmy Guimaraes-Young, Kurtis D Davies, Patricia Trevisan, et al.
The Oncologist|August 27, 2015
Targeting the WNT Signaling Pathway in Cancer TherapeuticsDavid Tai, Keith Wells, John Arcaroli, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 23, 2026
Copy Number-Low/TP53 Mutated Endometrial Cancer With Wild Type p53 Immunoexpression: Implications for Risk Stratification and Management When Using Next Generation Sequencing for Molecular ClassificationJoseph T Rabban, Rebecca J Wolsky, Neslihan Kayraklioglu, et al.
Frontiers in Medicine|February 8, 2021
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non-small Cell Lung Cancer: Focus on Testing for <i>RET</i> FusionsRoy S Herbst, Dara L Aisner, Joshua R Sonett, et al.
Pageof 13